In England, the monoclonal antibody drug Xevudy has been approved, which has been found to reduce the risk of hospitalization and death from the new type of coronavirus by 79%.
The Medicines and Healthcare products Regulatory Authority (MHRA) in the UK have stated that Xevudy is safe and effective in reducing the risk of death.
It is intended for people with mild to moderate infection with corona and who are at risk of developing serious diseases.
In the statement, it was indicated that Xevudy is the second approved monoclonal antibody treatment after the monoclonal antibody “Ronapreve” that was developed to treat the Corona virus.
The statement said that this drug, developed by Vir Biotechnology with GSK, is most effective when taken in the early stages of infection.
Therefore the MHRA recommends using the medication as soon as possible and within five days of symptoms appearing.
The statement said: “A single dose of a monoclonal antibody was found to reduce the risk of hospitalization.
and reduce the risk of death by 79 percent in adults at high risk of symptomatic MERS-CoV infection.
It was also confirmed that the drug was approved for people aged 12 years and over and weighing more than 40 kilograms.
Health Minister Sajid Javid also said in a statement on social media that the US National Health Department has approved a new treatment against the Coronavirus.
“We will closely monitor how effective Xevudy is against Omicron, and are working with the NHS on distribution plans.”